U.S. Biotech Stock News

If you are wondering whether Oshkosh is actually good value at its current share price, this article walks through the key numbers so you can judge that for yourself. The stock last closed at US$150.77, with returns of 6.4% over 7 days, 16.0% over 30 days, 14.0% year to date, 63.2% over 1 year, 70.4% over 3 years and 71.0% over 5 years, which puts recent valuation questions front and center. Recent headlines around Oshkosh have focused on its position in the capital goods space and investor...

VinFast’s latest delivery update and what it means for VFS stock VinFast Auto (VFS) reported preliminary Vietnam deliveries of 27,649 electric vehicles for December 2025 and 175,099 for the full year, building on guidance that 2025 global deliveries could approach 200,000 vehicles. See our latest analysis for VinFast Auto. These delivery updates arrive after a busy period for VinFast Auto. The company recently closed a US$470.6m shelf registration and issued fresh guidance that 2025 global EV...

Mereo BioPharma Group recently reported that its Phase 3 Orbit and Cosmic trials of setrusumab in osteogenesis imperfecta missed their primary fracture reduction endpoints but achieved strong statistical improvements in bone mineral density, while also updating investors that its approximately US$41,000,000 cash balance at 31 December 2025 is expected to fund operations to mid-2027. Alongside reassessing the future of setrusumab with partner Ultragenyx, Mereo is pushing ahead with a single...

If you are trying to figure out whether Trade Desk shares offer fair value at around US$37.13, you are in the right place because this article focuses squarely on what that price might represent. The stock has seen mixed returns, with a 3.9% decline over the last 7 days, a 2.6% gain over 30 days, and longer term returns of 1.5% decline year to date, 69.0% decline over 1 year, 18.7% decline over 3 years, and 54.2% decline over 5 years. These moves sit against a backdrop of ongoing interest in...

If you are wondering whether Autoliv’s current share price lines up with its underlying value, this breakdown is designed to walk you through the key numbers that matter. Autoliv shares last closed at US$128.45, with returns of 4.2% over 7 days, 5.9% over 30 days, 5.2% year to date, 36.0% over 1 year and 71.8% over 3 years. This naturally raises questions about how much of this performance is already reflected in the price. Recent attention on Autoliv has centered on its position in vehicle...

If you are wondering whether Barrick Mining is still offering value at around US$49.95, you are not alone. The stock's recent run has many investors reassessing what a fair price looks like. The share price sits at US$49.95 after returns of 5.7% over 7 days, 15.3% over 30 days, 13.3% year to date, 222.0% over 1 year and 191.0% over 3 years, with a 5 year return of 141.7% putting those shorter term moves into a wider context. Recent coverage has focused on how Barrick Mining's performance and...

If you are wondering whether Tenet Healthcare's current share price reflects its underlying worth, you are not alone. This article is built to help you think through that question calmly and clearly. The stock last closed at US$195.19, with a 1 year return of 50.1% and a 3 year return of 265.4%. Shorter term moves have been softer, with a 7 day return of a 3.4% decline, a 30 day return of a 1.1% decline, and a year to date return of a 2.1% decline. Recent attention on Tenet Healthcare has...

Earlier this month, Mobileye announced that a US-based automaker selected its EyeQ6H chip to power future hands-free Surround ADAS on millions of vehicles globally, adding an estimated 9 million units to more than 19 million projected EyeQ6H-based systems. The deal underlines how Mobileye’s vertically integrated, software-defined Surround ADAS platform, leveraging up to 11 sensors and REM crowdsourced data, is being positioned as a standard feature across mainstream and premium models as...

Palantir Technologies: recent performance snapshot Palantir Technologies (PLTR) has drawn attention after a period where the stock showed a 0.3% one day decline and small negative moves over the past week and month, alongside modestly positive year to date and past 3 months returns. Against this share price backdrop, investors are also watching fundamentals. These include reported annual revenue of US$3.9b and net income of US$1.1b, together with the company’s current value score of 0. See...

Context for CrowdStrike Holdings (CRWD) Investors CrowdStrike Holdings (CRWD) shares have been moving without a clear single news catalyst, which can make recent performance and valuation feel harder to interpret for you as an investor. Over the past month, the stock shows a return of about a 5.7% decline, with a roughly 4.9% decline over the past 3 months and a small gain year to date. That mix of short term weakness and a positive 1 year total return of about 26.8% raises natural questions...

Earlier this month, Teladoc Health launched nationwide enhancements to its long-running 24/7 Care virtual urgent care service, expanding treatable conditions, integrating specialist consults, using claims and Health Information Exchange data for preventive care, and enabling real-time prescription benefit checks. A distinctive aspect of this update is the use of integrated data and on-the-spot specialist input to resolve most issues within a single visit while prompting many patients to act...

Madrigal’s new Pfizer partnership puts MASH combinations in focus Madrigal Pharmaceuticals (MDGL) just signed an exclusive global license agreement giving Pfizer rights to ervogastat, a clinical-stage oral DGAT-2 inhibitor. This agreement directly targets future combination approaches in metabolic liver disease. The deal centers on DGAT-2’s role in triglyceride assembly and liver fat storage, an area closely linked to inflammation in MASH. Investors now have a new data point to watch as...

Terns Pharmaceuticals recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, outlining progress across its pipeline programs. Investor attention has centered on interim Phase 1 CARDINAL ASH data for TERN-701, which points to a potentially best-in-class profile with encouraging deep molecular responses. Next, we’ll examine how the promising TERN-701 Phase 1 CARDINAL data shapes Terns Pharmaceuticals’ investment narrative and future development...

TransDigm Group (TDG) caught investor attention after reporting Q3 revenue of US$2.44b, exceeding analyst expectations by 1.6%, and surpassing internal guidance for fiscal 2025 revenue and EBITDA, according to management. See our latest analysis for TransDigm Group. The latest earnings surprise appears to have reinforced an already strong run, with a 10.2% 1 month share price return and a 13.96% 3 month share price return, alongside a 1 year total shareholder return of 17.64% that sits within...

If you are wondering whether Fiserv's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. Fiserv shares last closed at US$67.50, with returns of a 1.8% decline over 7 days, a 2.1% decline over 30 days, a 2.9% gain year to date, and declines of 67.0% over 1 year, 34.6% over 3 years and 38.2% over 5 years. Recent headlines around Fiserv have focused on its role as a major provider of payments and financial...

Recently, Acadia Healthcare reiterated its 2025 revenue guidance of US$3.28 billion to US$3.30 billion while flagging a US$25 million to US$30 million EBITDA headwind from a new New York Medicaid policy restricting reimbursement for out-of-state behavioral health care. This policy change highlights Acadia’s sensitivity to state-level Medicaid decisions and the operational and earnings pressure that reimbursement shifts can create. We’ll now examine how the New York Medicaid reimbursement...

Woodward recently received an upgrade to a Zacks Rank #1 (Strong Buy), reflecting improved earnings estimates that analysts interpret as a sign of strengthening business conditions. This upgrade places Woodward in the top tier of Zacks-covered companies for earnings estimate revisions, highlighting growing analyst conviction around its underlying performance outlook. We’ll now examine how this Zacks upgrade, built on improving earnings estimates, could influence Woodward’s existing...

First Watch Restaurant Group (FWRG) has put expansion at the center of its latest update, reporting record preliminary 2025 operational results that include 64 new restaurants across 23 states, as well as same-restaurant sales and traffic growth. See our latest analysis for First Watch Restaurant Group. The strong preliminary 2025 update and fresh Boston opening come after a mixed share price pattern, with a 7.81% year to date share price return but a 10.77% decline in 1 year total...

Event context and recent performance Science Applications International (SAIC) has been drawing attention after recent share price moves, with the stock last closing at $108.06. That has come alongside modest annual revenue and net income growth. Over the past month, SAIC shares show a 6.38% return, with the past 3 months at 11.54% and year to date at 6.76%. The 1 year total return stands at a 5.63% decline. See our latest analysis for Science Applications International. SAIC’s recent 11.54%...

GeneDx Holdings (WGS) is back in focus after issuing preliminary 2025 results and fresh 2026 guidance, outlining revenue expectations tied to exome and genome volumes, along with new product launches and data partnerships. See our latest analysis for GeneDx Holdings. Despite a sharp 1 day share price return of 4.8% decline and a 30 day share price return of 26.2% decline that suggest sentiment has cooled after the guidance update, the 1 year total shareholder return of 53.2% and a very large...

Recently, Oakmark Funds highlighted Gartner, Inc. as a global research leader and disclosed that it had been buying shares after AI-related worries pressured the stock. At the same time, Gartner outlined nine future of work trends centered on AI’s impact on employees and HR, underscoring its role as both an advisor on, and subject of, AI-driven change. We’ll now examine how renewed fund-manager confidence in Gartner’s resilience to AI disruption may influence the company’s existing...

Recent analyst upgrades and increased confidence in Colgate-Palmolive (CL), tied to early growth signals in emerging markets and lower reliance on the US, have renewed attention on how the stock is currently priced. See our latest analysis for Colgate-Palmolive. The recent analyst upgrades, alongside a series of rating revisions across the street, appear to have coincided with stronger trading interest. Colgate-Palmolive’s 7 day share price return of 9.68% and year to date share price return...

IPG Photonics (IPGP) is back in focus after reporting strong third quarter results tied to electric vehicle and stationary battery welding demand, as well as launching its IPG Defense unit headquarters in Huntsville, Alabama. See our latest analysis for IPG Photonics. The recent quarterly update and expansion into defense have arrived after a 90 day share price return decline of 10.28% and a 5 year total shareholder return decline of 69.12%, which suggests long term momentum has been weak...

What J. M. Smucker’s recent returns suggest right now With no single headline event driving attention to J. M. Smucker (SJM), many investors are looking at the stock’s recent performance, valuation metrics, and fundamentals to understand how it currently stacks up. See our latest analysis for J. M. Smucker. Recently, J. M. Smucker’s share price return has picked up, with a 1-day move of 2.68% and a 7-day gain of 9.27%, while its 1-year total shareholder return of 8.02% comes against a weaker...